NASDAQ:VKTX - Viking Therapeutics Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Buy
Consensus Price Target: $16.00
Forecasted Upside: 146.15 %
Number of Analysts: 5
Breakdown:
0 Sell Ratings
0 Hold Ratings
5 Buy Ratings
0 Strong Buy Ratings

^$6.50 As of 09/16/2021 03:20 PM ET

▲ +0.01 (0.15%)

1 month | 3 months | 12 months

Get New Viking Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for VKTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VKTX

^$16.00

▲ +146.15% Upside Potential

This price target is based on 5 analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $16.00, with a high forecast of $21.00 and a low forecast of $13.00. The average price target represents a 146.15% upside from the last price of $6.50.

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in Viking Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/24/2020

0 strong buy ratings
13 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/22/2020

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/20/2020

0 strong buy ratings
11 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

12/19/2020

0 strong buy ratings
10 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

3/19/2021

0 strong buy ratings
9 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/17/2021

0 strong buy ratings
8 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

8/16/2021

0 strong buy ratings
5 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

9/15/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
7/29/2021	Raymond James	Boost Price Target	Outperform	$12.00 ➝ $13.00	High
6/20/2021	SVB Leerink	Initiated Coverage	Buy	$18.00	Low
6/18/2021	B. Riley	Reiterated Rating	Buy	$15.00	High
6/17/2021	HC Wainwright	Reiterated Rating	Buy	$21.00	Medium
5/25/2021	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$27.00 ➝ $12.00	High
5/3/2021	SVB Leerink	Reiterated Rating	Buy	$18.00	High
1/22/2021	Stifel Nicolaus	Reiterated Rating	Buy	$13.00	Low
10/29/2020	Raymond James	Boost Price Target	Strong-Buy	$25.00 ➝ $27.00	Medium
9/11/2020	William Blair	Reiterated Rating	Buy		Low
9/10/2020	B. Riley	Reiterated Rating	Buy	$15.00	High
9/1/2020	BTIG Research	Boost Price Target	Buy	$9.00 ➝ $12.00	High
8/31/2020	Chardan Capital	Boost Price Target	Buy	$15.00 ➝ $20.00	Medium
8/28/2020	HC Wainwright	Boost Price Target	Buy	$18.00 ➝ $21.00	High
8/6/2020	Raymond James	Reiterated Rating	Buy	$25.00	Medium
7/30/2020	B. Riley	Reiterated Rating	Buy	$12.00	High
7/29/2020	Chardan Capital	Reiterated Rating	Buy	$15.00	High
7/29/2020	Oppenheimer	Reiterated Rating	Buy	$12.00	High
7/29/2020	Stifel Nicolaus	Reiterated Rating	Buy	$14.00	High
6/4/2020	BMO Capital Markets	Initiated Coverage	Outperform	$14.00	Medium
5/5/2020	Chardan Capital	Initiated Coverage	Buy	$15.00	Medium
5/4/2020	B. Riley	Lower Price Target	Buy	$16.00 ➝ $12.00	High
5/2/2020	Maxim Group	Initiated Coverage	Buy	$14.00	High
5/1/2020	Oppenheimer	Initiated Coverage	Buy	$12.00	High
5/1/2020	Raymond James	Lower Price Target	Strong-Buy	$41.00 ➝ $25.00	High
5/1/2020	BTIG Research	Initiated Coverage	Buy	$9.00	High
4/30/2020	Stifel Nicolaus	Reiterated Rating	Buy	$14.00	High
4/3/2020	William Blair	Reiterated Rating	Buy		Low
3/18/2020	William Blair	Reiterated Rating	Buy		High
2/27/2020	HC Wainwright	Lower Price Target	Buy	$31.00 ➝ $18.00	High
1/2/2020	SVB Leerink	Reiterated Rating	Outperform		Medium
11/21/2019	B. Riley	Initiated Coverage	Buy	$16.00	Low
11/6/2019	Maxim Group	Reiterated Rating	Buy	$14.00	Low
11/5/2019	HC Wainwright	Reiterated Rating	Buy	$31.00	High
8/2/2019	HC Wainwright	Reiterated Rating	Buy	$31.00	High
7/16/2019	CIBC	Initiated Coverage	Outperform ➝ Outperform	$12.00	Low
7/16/2019	Oppenheimer	Initiated Coverage	Outperform	$12.00 ➝ $12.00	High
7/15/2019	Citigroup	Initiated Coverage	Outperform		High
6/25/2019	Stifel Nicolaus	Initiated Coverage	Buy ➝ Buy	$14.00	High
4/11/2019	HC Wainwright	Reiterated Rating	Buy	$31.00	Medium
3/29/2019	SVB Leerink	Upgrade	Market Perform ➝ Outperform	$10.00 ➝ $21.00	High
3/29/2019	William Blair	Reiterated Rating	Outperform		High
3/14/2019	Raymond James	Lower Price Target	Strong-Buy ➝ Strong-Buy	$43.00 ➝ $40.00	Low
3/14/2019	William Blair	Reiterated Rating	Outperform		High
3/14/2019	Maxim Group	Lower Price Target	Buy	$28.00 ➝ $20.00	High
2/22/2019	SVB Leerink	Initiated Coverage	Market Perform	$10.00	Medium
12/11/2018	B. Riley	Initiated Coverage	Buy ➝ Buy	$16.00	Low
11/19/2018	Raymond James	Upgrade	Outperform ➝ Strong-Buy	$43.00	High
11/13/2018	William Blair	Reiterated Rating	Buy		High
11/9/2018	Roth Capital	Set Price Target	Buy	$23.00	Medium
11/8/2018	Maxim Group	Reiterated Rating	Buy	$28.00	High
11/8/2018	HC Wainwright	Reiterated Rating	Buy	$31.00	N/A
10/1/2018	William Blair	Reiterated Rating	Market Perform		High
10/1/2018	HC Wainwright	Set Price Target	Buy	$31.00	High
9/19/2018	Raymond James	Set Price Target	Buy	$43.00	Low
9/19/2018	Roth Capital	Boost Price Target	Buy	$13.00 ➝ $24.00	High
9/19/2018	SunTrust Banks	Boost Price Target	Buy	$28.00	High
9/18/2018	Maxim Group	Reiterated Rating	Buy ➝ Buy	$14.00 ➝ $28.00	High
9/18/2018	Raymond James	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $43.00	High
9/18/2018	HC Wainwright	Set Price Target	Buy ➝ Buy	$15.00 ➝ $28.00	High
8/10/2018	William Blair	Reiterated Rating	Outperform		High
8/10/2018	HC Wainwright	Reiterated Rating	Buy	$15.00	High
7/20/2018	SunTrust Banks	Initiated Coverage	Buy	$14.00	High
6/28/2018	Raymond James	Initiated Coverage	Outperform	$15.00	Medium
6/1/2018	Roth Capital	Boost Price Target	Buy	$7.50 ➝ $13.00	Low
6/1/2018	Laidlaw	Boost Price Target	Buy	$10.00 ➝ $15.00	High
6/1/2018	HC Wainwright	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $15.00	High
5/31/2018	Maxim Group	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $14.00	High
5/10/2018	HC Wainwright	Set Price Target	Buy	$11.00	High
5/10/2018	Maxim Group	Set Price Target	Buy	$8.00	High
4/30/2018	William Blair	Initiated Coverage	Outperform		Low
3/26/2018	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$11.00	High
3/8/2018	Roth Capital	Set Price Target	Buy	$8.00	High
3/8/2018	Maxim Group	Reiterated Rating	Buy	$8.00	High
2/2/2018	Maxim Group	Reiterated Rating	Buy	$8.00	Low
12/12/2017	Maxim Group	Set Price Target	Buy	$8.00	Low
11/29/2017	Roth Capital	Set Price Target	Buy	$6.00	High
11/28/2017	Maxim Group	Set Price Target	Buy	$5.00 ➝ $8.00	High
11/21/2017	Roth Capital	Initiated Coverage	Buy ➝ Buy	$5.00	N/A
11/10/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$7.00	N/A
10/4/2017	Maxim Group	Reiterated Rating	Buy	$5.00	N/A
9/11/2017	Maxim Group	Reiterated Rating	Buy	$5.00	High
8/10/2017	Maxim Group	Set Price Target	Buy	$5.00	High
7/17/2017	HC Wainwright	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $7.00	Low
6/6/2017	Maxim Group	Set Price Target	Buy	$5.00	Low
5/11/2017	Maxim Group	Reiterated Rating	Buy	$5.00	High
3/27/2017	HC Wainwright	Reiterated Rating	Buy	$5.00	Medium
3/22/2017	Maxim Group	Set Price Target	Buy	$5.00	Medium
2/11/2017	Maxim Group	Set Price Target	Buy	$5.00	N/A
12/7/2016	Maxim Group	Set Price Target	Buy	$5.00	N/A
11/11/2016	Maxim Group	Set Price Target	Buy	$5.00	N/A
10/25/2016	Maxim Group	Set Price Target	Buy	$5.00	N/A
9/18/2016	HC Wainwright	Reiterated Rating	Buy	$6.00	N/A

(Data available from 9/16/2016 forward)

News Sentiment Rating

0.17 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

3 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

2/18/2021

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

3/20/2021

0 very positive mentions
0 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

4/19/2021

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

5/19/2021

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

6/18/2021

0 very positive mentions
1 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

7/18/2021

0 very positive mentions
3 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

8/17/2021

0 very positive mentions
4 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

9/16/2021

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Negative

No negative mentions tracked during this time.

Positive

americanbankingnews.com
9/7/2021
Viking Therapeutics, Inc. (NASDAQ:VKTX) Receives Average Rating of "Buy" from Analysts
americanbankingnews.com
9/4/2021
Financial Analysis: Viking Therapeutics (NASDAQ:VKTX) and Pacira BioSciences (NASDAQ:PCRX)
americanbankingnews.com
9/2/2021
-$0.21 Earnings Per Share Expected for Viking Therapeutics, Inc. (NASDAQ:VKTX) This Quarter
americanbankingnews.com
8/30/2021
Viking Therapeutics (NASDAQ:VKTX) Stock Price Up 6.4%

Very Positive

No very positive mentions tracked during this time.

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The firm's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Today's Range

Now: $6.50

$6.37

$6.53

50 Day Range

MA: $6.12

$5.58

$7.04

52 Week Range

Now: $6.50

$4.95

$10.09

Volume

4,182 shs

Average Volume

1,055,067 shs

Market Capitalization

$508.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.83

Frequently Asked Questions

What sell-side analysts currently cover shares of Viking Therapeutics?

The following Wall Street sell-side analysts have issued reports on Viking Therapeutics in the last twelve months: B. Riley, HC Wainwright, Raymond James, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for VKTX.

What is the current price target for Viking Therapeutics?

5 Wall Street analysts have set twelve-month price targets for Viking Therapeutics in the last year. Their average twelve-month price target is $16.00, suggesting a possible upside of 146.5%. HC Wainwright has the highest price target set, predicting VKTX will reach $21.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $13.00 for Viking Therapeutics in the next year.
View the latest price targets for VKTX.

What is the current consensus analyst rating for Viking Therapeutics?

Viking Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VKTX will outperform the market and that investors should add to their positions of Viking Therapeutics.
View the latest ratings for VKTX.

What other companies compete with Viking Therapeutics?

Other companies that are similar to Viking Therapeutics include Myovant Sciences, Organogenesis, NGM Biopharmaceuticals, Ironwood Pharmaceuticals, Indivior, Xencor, Revance Therapeutics, Centessa Pharmaceuticals, ADC Therapeutics, Trillium Therapeutics, Deciphera Pharmaceuticals, Nuvalent, Cassava Sciences, IVERIC bio and MacroGenics.

How do I contact Viking Therapeutics' investor relations team?

Viking Therapeutics' physical mailing address is 12340 EL CAMINO REAL SUITE 250, SAN DIEGO CA, 92130. The biotechnology company's listed phone number is (858) 704-4660 and its investor relations email address is [email protected] The official website for Viking Therapeutics is www.vikingtherapeutics.com.